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Summary
Background Lung delivery of plasmid DNA encoding the CFTR gene complexed with a cationic liposome is a potential 
treatment option for patients with cystic ﬁ brosis. We aimed to assess the eﬃ  cacy of non-viral CFTR gene therapy in 
patients with cystic ﬁ brosis.
Methods We did this randomised, double-blind, placebo-controlled, phase 2b trial in two cystic ﬁ brosis centres with 
patients recruited from 18 sites in the UK. Patients (aged ≥12 years) with a forced expiratory volume in 1 s (FEV1) of 
50–90% predicted and any combination of CFTR mutations, were randomly assigned, via a computer-based 
randomisation system, to receive 5 mL of either nebulised pGM169/GL67A gene–liposome complex or 0·9% saline 
(placebo) every 28 days (plus or minus 5 days) for 1 year. Randomisation was stratiﬁ ed by % predicted FEV1 (<70 vs 
≥70%), age (<18 vs ≥18 years), inclusion in the mechanistic substudy, and dosing site (London or Edinburgh). 
Participants and investigators were masked to treatment allocation. The primary endpoint was the relative change in 
% predicted FEV1. The primary analysis was per protocol. This trial is registered with ClinicalTrials.gov, number 
NCT01621867.
Findings Between June 12, 2012, and June 24, 2013, we randomly assigned 140 patients to receive placebo (n=62) or 
pGM169/GL67A (n=78), of whom 116 (83%) patients comprised the per-protocol population. We noted a signiﬁ cant, 
albeit modest, treatment eﬀ ect in the pGM169/GL67A group versus placebo at 12 months’ follow-up (3·7%, 95% CI 
0·1–7·3; p=0·046). This outcome was associated with a stabilisation of lung function in the pGM169/GL67A group 
compared with a decline in the placebo group. We recorded no signiﬁ cant diﬀ erence in treatment-attributable adverse 
events between groups. 
Interpretation Monthly application of the pGM169/GL67A gene therapy formulation was associated with a signiﬁ cant, 
albeit modest, beneﬁ t in FEV1 compared with placebo at 1 year, indicating a stabilisation of lung function in the 
treatment group. Further improvements in eﬃ  cacy and consistency of response to the current formulation are needed 
before gene therapy is suitable for clinical care; however, our ﬁ ndings should also encourage the rapid introduction of 
more potent gene transfer vectors into early phase trials.
Funding Medical Research Council/National Institute for Health Research Eﬃ  cacy and Mechanism Evaluation 
Programme.
Copyright © Alton et al. Open Access article distributed under the terms of CC BY. 
Introduction
Cystic ﬁ brosis has been a target for gene therapy since the 
CFTR gene was cloned in 1989.1 Lung disease is the main 
cause of morbidity and mortality in individuals with cystic 
ﬁ brosis, with a median age at death of 29 years (95% CI 
27–31).2 Early expectations of a rapid breakthrough were 
based on supposed ease of access to the target respiratory 
epithelium via inhaled aerosols. These hopes were 
tempered by the subsequent realisation that the airways 
are well defended, in keeping with their predominant 
function as conducting passages, rather than absorptive 
surfaces. 
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Various vectors for delivery of the CFTR gene into 
respiratory epithelial cells have been assessed. Viral 
approaches, including adenoviruses, adeno-associated 
viruses, and retroviruses, have faltered because of 
ineﬃ  cient transduction from the luminal surface and 
immune responses restricting the eﬃ  cacy of repeated 
application.3 As such, research from the UK Cystic 
Fibrosis Gene Therapy Consortium has initially focused 
on non-viral vectors. Formulation and delivery of plasmid 
DNA–liposome complexes have been reﬁ ned in a large 
series of preclinical studies,4,5 and safety,6,7 molecular 
eﬃ  cacy, and practical doses have been assessed in several 
phase 1 and 2a studies in patients with cystic ﬁ brosis.1,3 
We did this study to assess the clinical eﬃ  cacy of the 
non-viral CFTR gene–liposome complex pGM169/
GL67A8 after repeated delivery to the airways. 
Methods
Study design and participants
We did this randomised, double-blind, placebo-
controlled, phase 2b trial in two cystic ﬁ brosis centres 
with patients recruited from 18 sites in the UK. Eligible 
participants had diagnosed cystic ﬁ brosis, were aged 
12 years or older, had a forced expiratory volume in 1 s 
(FEV1) of 50–90% predicted, and had any combination of 
CFTR mutations. 
The protocol was approved by the National Research 
Ethics Committee and the local Research Committees at 
the two dosing sites and the 16 other referral centres. 
Each patient, or a parent, provided written informed 
consent, and children provided assent. 
Randomisation and masking
We randomly assigned patients (1:1), via a computer-based 
randomisation system, to receive nebulised pGM169/
GL67A or 0·9% saline (placebo). Randomisation was 
stratiﬁ ed by % predicted FEV1 (<70 vs ≥70%), age (<18 vs 
≥18 years), inclusion in the mechanistic substudy, and 
dosing site (London or Edinburgh). Participants in the 
mechanistic substudy were randomly assigned (2:1) to 
receive nebulised pGM169/GL67A or placebo, and could 
participate as part of either a nasal or bronchoscopy group, 
or both. Participants and investigators were masked to 
treatment allocation, with the randomisation code known 
only by pharmacy staﬀ  at the two dosing sites. 
Procedures 
Patients received 5 mL of either 0·9% saline or pGM169/
GL67A complex nebulised through a Trudell AeroEclipse 
II device (Trudell Medical International, London, ON, 
Canada) at 28 day intervals (plus or minus 5 days) for 
12 months. Each 5 mL dose of pGM169/GL67A contained 
13·3 mg of plasmid DNA and 75 mg of the GL67A lipid 
mixture. Routine treatments were continued throughout 
the study, except for DNase, which was withheld for 24 h 
before and after dosing. In addition to the nebulised 
dose, patients in the nasal group of the mechanistic 
substudy received 2 mL of placebo or pGM169/GL67A 
divided between nasal cavities via a nasal spray device at 
the time of each lung dose. Patients in the bronchoscopy 
group followed the standard protocol, but also underwent 
a bronchoscopy under general anaesthesia before the 
ﬁ rst dose and 28 days (plus or minus 5 days) after the 
ﬁ nal dose.
Outcomes
The primary eﬃ  cacy endpoint was the relative change in 
% predicted FEV1, calculated from the mean of two 
baseline values (at screening and before dosing on day of 
the ﬁ rst dose) to the mean of two values (2 and 4 weeks 
after last dose) at study completion. Secondary outcomes 
included additional measurements of lung function, CT 
scans, and Cystic Fibrosis Questionnaire-Revised 
(CFQ-R) scores.9 Exploratory endpoints included exercise 
testing, activity monitoring, and sputum inﬂ ammatory 
markers. Mechanistic endpoints were nasal or bronchial 
vector-speciﬁ c DNA, mRNA, and electrophysiological 
assessment of CFTR function. We did extensive safety 
assessments.
Statistical analysis
The statistical analyses were prespeciﬁ ed in a statistical 
analysis plan. With use of pilot data, we estimated the 
standard deviation of the relative change in % predicted 
FEV1 in the target cystic ﬁ brosis population to be 10% 
over 12 months. A total sample size of 120 assessable 
Research in context
Evidence before this study
We searched PubMed between June 1, 1992, and March 1, 2015, 
for studies published that included the terms ”non-viral, gene 
therapy, cystic ﬁ brosis” or ”liposome, gene therapy, cystic ﬁ brosis”.
Added value of this study
We report the ﬁ rst trial of non-viral CFTR gene therapy for 
patients with cystic ﬁ brosis that is powered to detect clinically 
relevant pulmonary changes. Our study has progressed this ﬁ eld 
of research from phase 1 and 2a studies showing changes in 
molecular surrogates of CFTR function, to a phase 2b setting 
assessing changes in lung function in patients with a broad 
range of CFTR mutations. Additionally, our study shows that 
monthly repeated application of non-viral gene therapy can be 
safely administered to the lungs over a 1 year period.
Implications of all the evidence
By providing the ﬁ rst proof of concept that non-viral gene 
therapy can beneﬁ cially aﬀ ect lung function, follow-up studies 
can assess optimum dose, dosing interval, and patient 
stratiﬁ cation at trial entry. Our ﬁ ndings are likely to catalyse earlier 
translation of more eﬃ  cient vectors into ﬁ rst-in-man trials.
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patients would provide 90% power to detect a 6% 
diﬀ erence between groups in the mean change from 
baseline at a two-sided 5% signiﬁ cance level. This power 
calculation was conservative because covariate adjust-
ment can be expected to increase statistical power. We 
did analyses in the per-protocol population (primary 
analysis), predeﬁ ned as participants who received at least 
nine doses of pGM169/GL67A or placebo, and in the 
intention-to-treat population, who received at least one 
dose of pGM169/GL67A or placebo. 
We compared outcomes between groups with an 
ANCOVA model, with inclusion of the relevant baseline 
value, treatment allocation, and stratiﬁ cation factors 
(baseline predicted FEV1, age, dosing site, inclusion in 
substudy). Results are reported as adjusted mean 
diﬀ erences with corresponding 95% CIs. We assessed 
subgroup eﬀ ects by including the relevant interaction 
term in the ANCOVA model. To allow results from 
diﬀ erent endpoints to be plotted on a common scale, the 
estimated treatment eﬀ ects were standardised and 
presented as multiples of the underlying SD. No adjust-
ment was made to the p values to allow for multiplicity 
because the secondary endpoints were supportive and 
the corresponding p values were interpreted con ser-
vatively. We assessed bronchial and nasal biomarkers 
with a Mann–Whitney U test. A two-sided p value less 
than 0·05 was considered statistically signiﬁ cant.
The trial was overseen by an independent Data 
Monitoring and Ethics Committee and a Trial Steering 
Committee. This trial is registered with ClinicalTrials.
gov, number NCT01621867.
Role of the funding source
The funder of the study had no role in study design, data 
collection, data analysis, data interpretation, or writing of 
the report. The corresponding author had full access to 
all the data in the study and had ﬁ nal responsibility for 
the decision to submit for publication.
Results
Figure 1 shows the trial proﬁ le. Between June 12, 2012, 
and June 24, 2013, we randomly assigned 140 patients to 
receive placebo (n=62) or pGM169/GL67A (n=78), of 
whom 136 (97%) patients comprised the intention-to-treat 
population and 116 (83%) patients comprised the per-
protocol population (ﬁ gure 1). Reasons for discontinuation 
in the intention-to-treat population were similar between 
groups (appendix). Baseline characteristics were similar 
between the two groups (table 1). Unless indicated 
otherwise, all subsequent details relate to the per-protocol 
population. 
114 (98%) patients had paired pre-treatment and post-
treatment measurements of % predicted FEV1. Of the two 
patients (both in the placebo group) who did not have 
paired measurements, one patient could not do the test 
because of a surgery-related pneumothorax and one 
withdrew because of time commitments and was 
unavailable for follow-up measurements. We recorded a 
signiﬁ cant ANCOVA-adjusted treatment eﬀ ect in the 
pGM169/GL67A group versus placebo at 12 months’ 
follow-up (3·7%, 95% CI 0·1–7·3; p=0·046; ﬁ gure 2) The 
relative changes within each of the individual groups were 
–4·0% (95% CI –6·6 to –1·4) in the placebo group and 
–0·4% (–2·8 to 2·1) in the pGM169/GL67A group 
(ﬁ gure 2). Post-hoc analysis showed that 21 (18%) patients 
(n=6 in the placebo group and n=15 in the pGM169/GL67A 
group) had an improvement in % predicted FEV1 of 5% or 
more of their individual baseline values. For comparison, 
the treatment eﬀ ect in patients in the inten tion-to-treat 
191 patients invited for screening
40 excluded
13 had FEV1 <50%
19 had FEV1 >90%
4 were clinically unstable
3 had clinically signiﬁcant liver disease
1 absence of evidence of cystic ﬁbrosis 
diagnosis
151 eligible for inclusion
11 discontinued
9 withdrew consent
2 developed exclusion criteria
140 randomised
62 assigned to receive placebo
51 in main cohort
4 in bronchoscopy subgroup only
4 in nasal subgroup only
3 in both subgroups
78 assigned to receive pGM169/GL67A
52 in main cohort
9 in bronchoscopy subgroup only
10 in nasal subgroup only
7 in both subgroups
2 discontinued
1 clinically unstable
1 withdrew consent
2 discontinued
2 withdrew consent
60 received placebo
6 discontinued
1 commenced ivacaftor
1 developed exclusion 
criteria
4 withdrew consent
54 received at least nine doses
76 received pGM169/GL67A
14 discontinued
2 commenced ivacaftor
3 developed exclusion 
criteria
1 missed three or more 
doses
8 withdrew consent
62 received at least nine doses
Intention 
to treat
Per protocol
Figure 1: Trial proﬁ le
Numbers of patients in the intention-to-treat population are unequal because of the 2:1 allocation in the 
mechanistic substudy. FEV1=forced expiratory volume in 1 s.
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population who had spirometry measure ments both 
before dosing and within the protocol-deﬁ ned window 
after their ﬁ nal dose (n=56 in the placebo group and n=65 
in the pGM169/GL67A group) was 3·6% (95% CI 0·2–7·0; 
p=0·039), with the 20 patients included in the intention-to-
treat, but not per-protocol, analysis, receiving a mean of 
3·7 doses (SD 1·9). 
Figure 3 summarises changes in a range of secondary 
outcomes. The treatment eﬀ ect was signiﬁ cant for FVC 
(p=0·031; appendix) and CT gas trapping (p=0·048), but 
not for other measures of lung function, imaging, and 
quality of life (ﬁ gure 3). We assessed whether a responder 
subgroup could be identiﬁ ed; the appendix summarises 
the prespeciﬁ ed subgroups. We noted no signiﬁ cant 
diﬀ erences in the primary outcome treatment eﬀ ect with 
respect to sex, age, CFTR mutation (phe508del homo-
zygous vs other), Pseudomonas colonisation, predominant 
smaller or larger airway disease on CT at presentation, 
concurrent drugs, or treatment-associated adverse events 
(appendix). Although some subgroups had larger 
treatment eﬀ ects than others, these results were typically 
due to a greater decline in FEV1 in the placebo group, 
rather than to any diﬀ erence of eﬀ ect in the pGM169/
GL67A group (appendix). Stratiﬁ cation by baseline 
% predicted FEV1 suggested a diﬀ erence, albeit non-
signiﬁ cant, in treatment eﬀ ect between patients with 
more severe disease (FEV1 49·6–69·2% predicted), who 
had a treatment eﬀ ect of 6·4% (95% CI 0·8–12·1), and 
those with less severe disease (69·6–89·9% predicted), 
who had a treatment eﬀ ect of 0·2% (–4·6 to 4·9; 
pinteraction=0·065; appendix). In patients with more severe 
disease, post-trial and pre-trial changes in both the 
placebo group (–4·9%) and the pGM169/GL67A group 
(1·5%) contributed to the treatment eﬀ ect. Secondary 
outcomes showed a similar trend favouring the more 
severe category (appendix).
Patients in both treatment groups received a median of 
three (IQR one to ﬁ ve) courses of oral or intravenous 
antibiotics during the trial. Speciﬁ cally, we assessed co-
administered antibiotics during the critical analysis 
Placebo group (n=54) pGM169/GL67A group (n=62)
Age (years) 26·0 (13·0) 23·6 (10·8)
<18 years old 17 (31%) 23 (37%)
≥18 years old 37 (69%) 39 (63%)
Sex 
Female 25 (46%) 31 (50%)
Male 29 (54%) 31 (50%)
Centre distribution number
Edinburgh 24 (44%) 22 (35%)
London 30 (56%) 40 (65%)
Height (cm) 165·0 (10·6) 163·6 (10·9)
Weight (kg) 61·6 (15·6) 61·0 (15·7)
FEV1 (% predicted) 69·0 (9·9) 69·9 (11·1)
Body-mass index (kg/m²) 22·4 (4·4) 22·4 (4·5)
Mutation class
Phe508del/Phe508del 26 (48%) 31 (50%)
Phe508del/class 1–6 22 (41%) 23 (37%)
Not Phe508del/class 1 1 (2%) 3 (5%)
Heterozygous/homozygous class 3–6 2 (4%) 2 (3%)
Phe508del/unknown class 3 (6%) 3 (5%)
Data are mean (SD) or n (%), unless otherwise indicated.
Table 1: Baseline and demographic characteristics  
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C
Figure 2: Timecourse of the primary outcome response to either placebo or 
pGM169/GL67A (A) and the individual patient responses in the pGM169/
GL67A (B) and placebo (C) groups 
Error bars in panel A show the standard error of the mean. Primary outcome 
measurements were taken at each treatment visit before administration of 
study drugs. Pre and post values indicate the mean of two measurements at the 
respective timepoints. Positive values in panels B and C show an improvement. 
FEV1=forced expiratory volume in 1 s.
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period from dose 11 to the end of the trial. Numbers of 
patients receiving any additional antibiotics were 26 
(48%) in the placebo group and 30 (51%) in the pGM169/
GL67A group (χ² p=0·774). Thus, the observed FEV1 
treatment eﬀ ect was considered to be independent of 
concurrent antibiotic courses. 
No clinically relevant pattern of changes could be 
distinguished in the exploratory outcomes of activity and 
exercise monitoring and serum and sputum inﬂ am-
matory markers (appendix). In the bronchoscopy group 
of the substudy, vector-speciﬁ c DNA increased in 
12 (86%) of 14 patients in the pGM169/GL67A group and 
was below the limit of quantiﬁ cation in all (n=7) placebo 
samples (p=0·001; ﬁ gure 4A); vector-speciﬁ c mRNA was 
below the level of sensitivity in both groups (appendix). 
Changes in basal post-trial and pre-trial potential 
diﬀ erence values did not diﬀ er signiﬁ cantly in either 
group (appendix). Figure 4B shows bronchial chloride 
responses using the mean of all interpretable tracings 
for each patient; a negative value indicates a change in 
the non-cystic ﬁ brosis direction. Patients in the placebo 
group (n=7) had a median change (post-trial minus pre-
trial) of 3·1 mV (range 9·3 to –1·2) and those in the 
pGM169/GL67A group (n=10) had a change of –1·3 mV 
(4·0 to –5·8; p=0·032; ﬁ gure 4B). Five (50%) of ten 
patients in the pGM169/GL67A group had values that 
were more negative than the largest response in the 
placebo group (ﬁ gure 4). In the same analysis with only 
the most negative value recorded for each patient at any 
timepoint, patients in the placebo group had a median 
post-trial minus pre-trial change of 2·6 mV (range 9·3 to 
–1·2) and those in the pGM169/GL67A group had a 
change of –2·8 mV (4·0 to –16·8 mV; p=0·088; 
ﬁ gure 4C). Six (60%) patients in the pGM169/GL67A 
group had values that were more negative than the 
largest response in the placebo group (ﬁ gure 4). The 
appendix shows absolute bronchial potential diﬀ erence 
values. 
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54/61
54/61
54/60
54/61
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52/61
27/22
54/60
54/61
48/55
51/61
Primary endpoint
FEV1
Lung function
FVC
MEF25–75
Lung clearance index
CT
Bronchiectasis extent
Bronchiectasis severity
Wall thickness
Large airway mucus plugs
Small airway mucus plugs
Gas trapping
Health-related quality of life*
Physical functioning
Respiratory symptoms
Safety
C-reactive protein
Erythrocyte sedimentation rate
White blood cells
KCOc
TLCOc
Alveolar volume
Sputum 24 h weight
 69·48 (10·50)
 83·94 (11·54)
 1·63 (0·71)
 10·78 (2·45)
 1·92 (0·74)
 1·80 (0·74)
 1·84 (0·60)
 0·81 (0·38)
 0·85 (0·33)
 4·65 (12·85)
 82·87 (18·9)
 78·78 (14·25)
 7·32 (9·67)
 12·88 (11·01)
 8·58 (2·79)
 1·91 (0·22)
 8·02 (2·10)
 4·23 (1·12)
 10·96 (11·73)
Placebo/pGM169/GL67A (N) Pre-treatment Absolute 
treatment eﬀect
Standardised 
treatment eﬀect
Adjusted 
p value
0·046
0·031
0·362
0·187
0·564
0·116
0·146
0·369
0·061
0·048
0·584
0·425
0·057
0·272
0·176
0·257
0·302
0·331
0·239
Favours placebo Favours pGM169/GL67A
Standardised treatment eﬀect
3·66 (0·07 to 7·25)
3·03 (0·29 to 5·78)
0·07 (–0·08 to 0·22)
–0·28 (–0·71 to 0·14)
–0·03 (–0·13 to 0·07)
–0·08 (–0·17 to 0·02)
–0·09 (–0·21 to 0·03)
–0·03 (–0·1 to 0·04)
–0·07 (–0·15 to 0·00)
–3·49 (–6·96 to –0·03)
1·82 (–4·75 to 8·39)
2·08 (–3·06 to 7·22)
–4·82 (–9·8 to 0·15)
–1·86 (–5·21 to 1·48)
–0·52 (–1·28 to 0·24)
0·03 (–0·02 to 0·08)
0·18 (–0·16 to 0·51)
0·07 (–0·07 to 0·21)
–2·96 (–7·97 to 2·05)
0·39 (0·01 to 0·77)
0·42 (0·04 to 0·80)
0·18 (–0·21 to 0·56)
0·26 (–0·13 to 0·66)
0·11 (–0·27 to 0·50)
0·31 (–0·08 to 0·69)
0·28 (–0·1 to 0·66)
0·18 (–0·21 to 0·56)
0·37 (–0·02 to 0·75)
0·39 (0·00 to 0·77)
0·11 (–0·28 to 0·50)
0·16 (–0·23 to 0·54)
0·39 (–0·01 to 0·80)
0·21 (–0·17 to 0·59)
0·26 (–0·12 to 0·64)
0·23 (–0·17 to 0·63)
0·21 (–0·19 to 0·60)
0·19 (–0·20 to 0·57)
0·36 (–0·25 to 0·98)
Figure 3: Forest plot showing secondary outcome responses to placebo or pGM169/GL67A
Data are mean (SD) or mean (95% CI), unless otherwise indicated. The size of the circles is proportional to the number of patients represented and the error bars show 
95% CIs. Values shown for FEV1 are the relative change in the % predicted FEV1. To allow results from diﬀ erent endpoints to be plotted on a common scale, the 
estimated treatment eﬀ ects were standardised to be presented as multiples of the underlying SD (standardised treatment eﬀ ect). FEV1=forced expiratory volume in 1 s. 
MEF25–75=mid-expiratory ﬂ ow between 25% and 75% of FVC. KCOc=diﬀ usion capacity of the alveolar capillary membrane, corrected for haemoglobin concentrations. 
TLCOc=transfer factor of the lung for carbon monoxide, corrected for haemoglobin concentrations. *Refers to scores from the Cystic Fibrosis Questionnaire-Revised.
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In patients in the nasal group of the substudy, vector-
speciﬁ c DNA increased in all the 17 patients given 
pGM169/GL67A. Despite apparent pGM169 con tami-
nation in some samples, the change in pGM169 con cen-
trations diﬀ ered signiﬁ cantly between the groups 
(appendix); no vector-speciﬁ c mRNA was quantiﬁ able in 
either group. We noted no signiﬁ cant changes in the 
baseline, zero chloride, or isoprenaline responses 
(appendix). Four (29%) of 14 pGM169/GL67A patients 
had mean post-trial minus pre-trial treatment responses 
(ranging from –3·4 mV to –7·0 mV) that were more 
negative than the largest response in the placebo group 
(n=6; appendix). The appendix shows absolute nasal 
potential diﬀ erence values. 
All patients had adverse events, with no signiﬁ cant 
diﬀ erence between groups for either total events or 
within the nine predeﬁ ned adverse event categories 
(table 2). One patient in the placebo group and one 
patient in the pGM169/GL67A group discontinued study 
treatment because of adverse events (fatigue and 
increased respiratory symptoms and ﬂ u-like symptoms, 
respectively). We recorded six serious adverse events, all 
in the pGM169/GL67A group (appendix). Neither the 
Data Monitoring and Ethics Committee nor the Trial 
Steering Committee regarded any serious adverse event 
as related to study drug; however, one event was 
considered to be possibly related to a trial procedure 
(bronchoscopy). We noted no clinically relevant changes 
in haematology, biochemistry, conversion of anti-CFTR 
T cells, anti-DNA antibodies, histology, or lipid staining 
(appendix) and no patients died during the study.
Discussion
We report the ﬁ rst trial of non-viral based gene therapy 
for cystic ﬁ brosis, powered to detect clinically relevant 
pulmonary changes. After monthly dosing for 1 year, we 
recorded evidence of a beneﬁ cial eﬀ ect of gene therapy 
versus placebo on FEV1. No eﬀ ect of sex, age, or whether 
patients were homozygous for the most common 
F508del CFTR mutation could be detected. No clinically 
important adverse events attributable to treatment with 
pGM169/GL67A were reported. 
Although these ﬁ ndings are encouraging, they should 
be put into perspective. We noted a stabilisation of FEV1 
in the pGM169/GL67A group rather than an improve-
ment. This stabilisation took place over a 1 year period 
and further work will be needed to see if this eﬀ ect is 
maintained. The reduction in FEV1 in the placebo group 
was within the range reported in some other prospective 
trials10–12 and is consistent with a median survival of 
29 years, but is greater than would be expected from 
registry data.2 Three factors are likely to have inﬂ uenced 
this diﬀ erence. First, the requirement for clinical 
stability at trial entry meant that patients might have 
been at their optimum respiratory health at this stage. 
Second, the enthusiasm of patients to enter the trial, 
accompanied by a focus on self-care, might have 
resulted in short-term improve ments in lung function 
during the recruitment period. Both factors are likely to 
lead to a subsequent decline in lung function as patients 
regress to their mean values. Third, we included all 
available data, whether from stable patients or those 
with exacerbations, by contrast with registry data, 
which focuses on measurements obtained at annual 
review. Stabilisation of lung disease in itself is a 
worthwhile aim and we would caution against the bar 
being set too high for novel therapeutics in cystic 
ﬁ brosis populations with an unselected range of 
mutations. The large response to ivacaftor in patients 
with class III mutations takes place in the context of 
correctly localised CFTR protein. By contrast, much 
smaller improvements in lung function were shown in 
the ivacaftor–lumacaftor trial for the most common 
mutation (phe508del) in which the CFTR protein is 
misfolded and mislocalised.13 
Placebo group (n=54) pGM169/GL67A group (n=62)
Lower airway respiratory symptoms 7·9 9·0
Gastrointestinal symptoms 2·1 1·8
Fever or ﬂ u-like symptoms 1·1 1·4
Headache 1·2 1·1
Upper airway symptoms 2·3 3·4
Elevated liver function tests 0·3 0·4
Haematuria 0·2 0·2
Isolated raised inﬂ ammatory markers 0·8 0·7
Other 3·2 3·3
Total 19·1 21·2
Data are mean number of times the respective symptom was experienced by each patient during the trial. Values were 
calculated by dividing the total number of the relevant adverse event by the total number of relevant patients in that group.
Table 2: Adverse events
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Figure 4: Assessment of DNA from bronchial brushings in the placebo (n=7) and pGM169/GL67A (n=14) 
subgroups (A) and the response of the bronchial epithelium to perfusion with a zero chloride solution 
containing isoprenaline 10 μM (B, C) 
Horizontal bars show median values. Each circle in panel A represents an individual patient. Each symbol in panels 
B and C shows the change in response from trial start to ﬁ nish for the relevant treatment in an individual patient. 
Of the 16 participants in the bronchoscopy subgroup, 15 individuals had post-dose bronchoscopies, of whom 
14 individuals generated samples for DNA and mRNA molecular analysis. The plotted value in panel B is the mean 
of all interpretable recordings (range 1–3), and in panel C is the most negative value obtained from all interpretable 
recordings, at each timepoint for that patient. A more negative value is in the non-cystic ﬁ brosis direction. 
LOQ=limit of quantiﬁ cation, PBNQ=positive but not quantiﬁ able. 
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The response in our study was heterogeneous, with 
apparent responders and non-responders. The data 
suggest that an approximate doubling of treatment eﬀ ect 
was achieved in patients with more severe disease 
stratiﬁ ed by baseline FEV1, supported by trends in other 
clinically relevant secondary measures. A larger trial with 
a stratiﬁ ed trial entry design, powered to assess 
subgroups, and that addresses the mechanisms of 
response heterogeneity, will be important to verify or 
refute these data. This diﬀ erential response could relate 
to the dose deposited in the airways; in patients with 
lower baseline FEV1 the relatively more obstructed 
smaller airways result in a larger proportion of the 5 mL 
dose being deposited in the larger airways. In pre-trial 
studies we assessed airway deposition in patients with 
cystic ﬁ brosis with varying FEV1 severity with technetium-
99m labelled human serum albumin of similar droplet 
size (3–4 μm, using a diﬀ erent nebuliser system) to the 
pGM169/GL67A formulation. Bronchial airway 
(generations 2–8) fractional deposition was 2·9% of 
delivered dose (standard error of the mean [SEM] 0·2; 
n=33) in patients with 70–90% predicted FEV1 and 
roughly twice as great (6·0%, SEM 1·0; n=23) in those 
with 50–70% predicted FEV1. An additional contributory 
factor to this enhanced eﬃ  cacy might be the increased 
mitotic rate of more severely aﬀ ected tissues,14 which 
decreases the proportion of time that the nuclear 
membrane is intact, the membrane acting as a barrier to 
plasmid DNA entry to the nucleus. 
We cannot rule out that the changes recorded in the 
present study are the result of a non-speciﬁ c response to 
the pGM169/GL67A formulation. The placebo was 0·9% 
saline rather than a scrambled or CFTR-deleted plasmid–
liposome complex. We selected 0·9% saline partly on the 
basis of pragmatic ﬁ nancial considerations, but mainly 
for ethical considerations, not wishing to expose patients 
with cystic ﬁ brosis to ﬁ rst-in-man repeated pulmonary 
dosing of an untested product that might direct the 
expression of an immunologically active peptide or novel 
non-coding RNA molecule with deleterious biological 
functions. Furthermore, we wanted to compare pro-
gression on therapy with the natural history of the 
disease. In terms of alternative explanations for the 
eﬀ ects we noted, we know of no evidence that monthly 
nebulisation of 0·9% saline is deleterious to lung 
function, nor that liposome alone produces physiological 
improvements in either patients without,15 or those with16 
cystic ﬁ brosis. Delivery of non-CFTR encoding plasmid 
DNAs to the human airways has not been associated 
with a gain in CFTR chloride-channel function, nor 
improvement in any cystic ﬁ brosis-related assay,17,18 and 
plasmid DNA is generally associated with pro-inﬂ am-
matory, rather than non-speciﬁ c, beneﬁ cial eﬀ ects.19 We 
did not identify any pathophysiological changes in the 
airways, such as inﬂ ammation or remodelling, nor any 
changes in bacterial species that might otherwise explain 
the outcomes. Nevertheless, we cannot exclude that 
DNA–liposome complexes augment host defences, 
stimulate mucus clearance, or enhance bacterial killing 
to an extent undetectable on semi-quantitative routine 
culture. 
Results showing more robust changes in molecular 
CFTR surrogates would have been reassuring. Despite 
extensive optimisation of quantitative realtime-PCR 
assays, the pGM169-derived mRNA assay has poor 
sensitivity and is adversely aﬀ ected by the inclusion of 
high levels of total RNA or modest concentrations of 
pGM169 plasmid DNA. In ovine studies we have shown 
that a 20 mL nebulised dose of pGM169/GL67A, four 
times that used in the present trial, is the lower threshold 
for reproducible detection of mRNA with this assay in 
airway tissue samples (unpublished).6 Thus, our inability 
to detect pGM169-derived mRNA after delivery of 5 mL 
of pGM169/GL67A to the human airways, although 
disappointing, was not surprising. In human tissues, we 
have noted the low sensitivity of assays assessing vector-
speciﬁ c mRNA from human samples in vivo,16,20,21 and 
have noted the greater sensitivity of detection of 
electrophysiological changes, consistent with ﬁ ndings in 
this study.17,18,22 
The ratio of area sampled to area dosed is small. 
Although we recorded signiﬁ cant chloride secretory 
changes in the bronchial, but not the nasal, epithelium, 
we caution against placing undue weight on either 
observation. The size of the groups in the mechanistic 
substudy was limited by both the practicality of the 
procedures and the acceptability to patients of the 
additional invasive tests, leading to low statistical power 
for these measures. We would instead conclude that 
modest variable changes can be shown with currently 
available assays that remain insuﬃ  ciently sensitive to 
detect changes in low levels of CFTR function when 
assessed in vivo in humans; further optimisation in these 
or other assays is needed. 
Although we are encouraged by the ﬁ rst demonstration 
of a signiﬁ cant beneﬁ cial eﬀ ect in lung function 
compared with placebo associated with gene therapy in 
patients with cystic ﬁ brosis, the mean diﬀ erence was 
modest, only recorded in some individuals, and at the 
lower end of the range of results seen in clinical trials 
which result in changes in patient-related care.23,24 We did 
not formally assess infective exacerbations in view of the 
fairly small patient numbers in our study, but use of 
antibiotic courses as a surrogate identiﬁ ed no obvious 
treatment advantage. The treatment eﬀ ect is consistent 
with a clinically meaningful beneﬁ t from the perspective 
of the European Medicine Agency;25 however, further 
improvements in eﬃ  cacy and consistency of response to 
the current formulation, or its combination with CFTR 
potentiators, are needed before gene therapy is suitable 
for clinical practice. Furthermore, our ﬁ ndings should 
encourage the rapid introduction of more potent gene 
transfer vectors into early phase trials, now that much of 
the groundwork has been established. 
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The data reported here provide the ﬁ rst proof of 
concept that repeated administration of non-viral CFTR 
gene therapy can safely change clinically relevant 
parameters, providing another step along the path of 
translational cystic ﬁ brosis gene therapy.
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